Idera +5% AH on positive IMO-8400 data

|About: Idera Pharmaceuticals, Inc. (IDRA)|By:, SA News Editor

New preclinical data being presented by Idera (IDRA) demonstrates the ability of the company's IMO-8400 drug to "inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation."

Idera has opened enrollment for a Phase 1/2 trial to evaluate IMO-8400 for use in treating " patients with Waldenstr├Âms macroglobulinemia who are refractory to prior therapies," and expects patient treatment to start in Q2.

The company has also submitted a request to the FDA to "conduct a Phase 1/2 trial in patients with [diffuse large B-cell lymphoma] who harbor the MYD88 L265P mutation."